Blood cancers

Tazemetostat promising in RR follicular lymphoma

The novel EZH2 inhibitor tazemetostat has shown clinically meaningful benefit in patients with relapsing or refractory follicular lymphoma regardless of EZH2 mutation status. The phase 2 study, involving 99 patients from nine countries including Australia, tested 800mg tazemetostat orally twice daily in consecutive 28-day cycles. It found an overall response of 69% in patients with ...

Already a member?

Login to keep reading.

© 2021 the limbic